Augmented pro-inflammatory cytokines such as tumour necrosis factor-α (TNF-α) or interleukin-6 (IL-6) as well as autoantibodies arise in CRPS patients which can elicit pro-nociceptive effects in preclinical models [6–10]. This evidence concerns the gene IL6 and complex regional pain syndrome.